DE602004008771T2 - Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd) - Google Patents

Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd) Download PDF

Info

Publication number
DE602004008771T2
DE602004008771T2 DE602004008771T DE602004008771T DE602004008771T2 DE 602004008771 T2 DE602004008771 T2 DE 602004008771T2 DE 602004008771 T DE602004008771 T DE 602004008771T DE 602004008771 T DE602004008771 T DE 602004008771T DE 602004008771 T2 DE602004008771 T2 DE 602004008771T2
Authority
DE
Germany
Prior art keywords
amphetamine
isomer
pharmaceutical composition
release
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004008771T
Other languages
German (de)
English (en)
Other versions
DE602004008771D1 (de
Inventor
Richard A. Chevy Chase COUCH
A. Shire Pharmaceutical Development Rockville MICHAELS
Paul Exton HODGKINS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
Shire Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Canada Inc filed Critical Shire Canada Inc
Publication of DE602004008771D1 publication Critical patent/DE602004008771D1/de
Application granted granted Critical
Publication of DE602004008771T2 publication Critical patent/DE602004008771T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602004008771T 2003-02-10 2004-02-10 Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd) Expired - Fee Related DE602004008771T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44579303P 2003-02-10 2003-02-10
US445793P 2003-02-10
US47392503P 2003-05-29 2003-05-29
US473925P 2003-05-29
PCT/US2004/003821 WO2004071501A1 (en) 2003-02-10 2004-02-10 Enantiomeric amphetamine compositions for the treatment of adhd

Publications (2)

Publication Number Publication Date
DE602004008771D1 DE602004008771D1 (de) 2007-10-18
DE602004008771T2 true DE602004008771T2 (de) 2008-06-12

Family

ID=32871959

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004008771T Expired - Fee Related DE602004008771T2 (de) 2003-02-10 2004-02-10 Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd)

Country Status (10)

Country Link
US (1) US20040220277A1 (cg-RX-API-DMAC7.html)
EP (1) EP1626709B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006517232A (cg-RX-API-DMAC7.html)
KR (1) KR20050119106A (cg-RX-API-DMAC7.html)
AT (1) ATE372112T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004210671A1 (cg-RX-API-DMAC7.html)
CA (1) CA2515394A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004008771T2 (cg-RX-API-DMAC7.html)
ES (1) ES2293223T3 (cg-RX-API-DMAC7.html)
WO (1) WO2004071501A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
EP1874274A2 (en) * 2005-04-06 2008-01-09 Mallinckrodt Inc. Matrix-based pulse release pharmaceutical formulation
WO2007041571A1 (en) * 2005-10-03 2007-04-12 Cambrex Charles City, Inc. Improved method of making amphetamine free base
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
US10463633B2 (en) * 2010-04-23 2019-11-05 Kempharm, Inc. Therapeutic formulation for reduced drug side effects
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
WO2013059676A1 (en) * 2011-10-21 2013-04-25 Subhash Desai Compositions for reduction of side effects
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
IL288554B2 (en) * 2016-02-24 2024-02-01 Chemapotheca LLC Controlled release of amphetamine, drug meters and dosage forms with abuse deterrence
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
CA3221280A1 (en) 2021-06-03 2022-12-08 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
CA3239514A1 (en) * 2021-12-09 2023-06-15 Matthew J. Baggott Specialized combinations for mental disorders or mental enhancement

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056968A (en) * 1997-03-11 2000-05-02 Darwin Discovery Limited Pharmaceutical drug dosage forms providing different release rates
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
WO2000059481A1 (en) * 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
TWI291871B (en) * 2000-11-01 2008-01-01 Cognition Pharmaceuticals Llc Pharmaceutical compositions and use of amphetamine compounds for improving memory and learning
AU2003208170B2 (en) * 2002-02-28 2006-11-23 Birseck Pty Ltd Treatment of effect of chemicals with their ultradilute stereoisomers
AU2003231156A1 (en) * 2002-04-30 2003-11-17 Npd Llc Multi-phasic delivery via transmucosal absorption of appetite suppressants and craving reduction medicaments
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts

Also Published As

Publication number Publication date
ES2293223T3 (es) 2008-03-16
KR20050119106A (ko) 2005-12-20
WO2004071501A1 (en) 2004-08-26
DE602004008771D1 (de) 2007-10-18
CA2515394A1 (en) 2004-08-26
HK1091117A1 (en) 2007-01-12
EP1626709B1 (en) 2007-09-05
ATE372112T1 (de) 2007-09-15
EP1626709A1 (en) 2006-02-22
US20040220277A1 (en) 2004-11-04
JP2006517232A (ja) 2006-07-20
AU2004210671A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
DE69922964T2 (de) Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe
EP1626709B1 (en) Enantiomeric amphetamine compositions for the treatment of adhd
DE69735848T2 (de) Dosisform mit ansteigender dosisfreisetzung
DE69911240T2 (de) Zusammensetzungen, enthaltend mikronisiertes eplerenon
DE69315257T2 (de) Simethicon enthaltende Arzneimittel zur Behandlung gastrointestinaler Störungen
DE69730834T2 (de) Verfahren zur herstellung von festen oralen dosierungsformen von valsartan
DE69826290T2 (de) Pharmazeutische zusammensetzungen zur kontrollierten freigabe von wirkstoffen
DE69802543T3 (de) Verbesserte multipartikel-tablette mit schnellauflösbarkeit
EP1183015B1 (de) Mehrschichttablette zur verabreichung einer fixen kombination von tramadol und diclofenac
DE69434479T2 (de) Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe
DE60225331T2 (de) Pharmazeutische zusammensetzungen mit metformin und glibenclamid zur behandlung von diabetes mellitus typ ii
DE69720055T2 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
DE69209080T2 (de) Pharmazeutische zusammemsetzungen mit verzoegerter freigabe
DE60024320T2 (de) Orale zusammensetzungen für diabetes
DE69817848T2 (de) Monolithsysteme enthaltend mindestens einer wirkstoff, bestehend aus drei schichten mit unterschiedlichen freisetzungmechanismus
EP1372624B1 (de) Arzneimittel auf basis von tramadol
DE69619979T2 (de) Feste zusammensetzungen mit einem nicht-amorphem wirkstoff und polyäthylenoxyd
EP1113787A1 (de) Agitationsunabhängige pharmazeutische multiple-unit-retardzubereitungen und verfahren zu ihrer herstellung
DE112011101605T5 (de) Pharmazeutische Zusammensetzung umfassend Hydromorphon und Naloxon
DE60317993T2 (de) Pharmazeutische Zubereitung mit verzögerter Freisetzung zur oralen Wirkstoffverabreichung
DE60018629T2 (de) Carbamazepinformulierung mit verzögerter Freigabe
DE602006000819T2 (de) Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung
DE602004005734T2 (de) Pharmazeutische zusammensetzung mit kontrollierter freisetzung und verfahren zu ihrer herstellung
DE102013009114A1 (de) Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
DE69914472T2 (de) Levosimendanhaltige oral anzuwendende arzneimittel mit gesteuerter wirkstoffverabreichung

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SHIRE CANADA INC., ST. LAURENT, QUEBEC, CA

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee